Sun Pharma Declares ₹11 Interim Dividend; Q3FY26 Consolidated Sales Up 15.1% to ₹154,691 Crore
Sun Pharma declared an interim dividend of ₹11 per share. For Q3FY26, consolidated sales rose 15.1% YoY to ₹154,691 million. Net profit increased 16.0% YoY to ₹33,688 million. Nine-month sales grew 11.3% YoY to ₹436,604 million. India Formulation sales grew 16.2% to ₹49,986 million.
The announcement includes financial results and a dividend declaration, which are material events for investors.
The company reported positive financial results with increased sales and net profit, alongside a dividend declaration.
Sun Pharmaceutical Industries Limited announced its financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved the unaudited standalone and consolidated financial results.
The company declared an interim dividend of ₹11 per equity share for the financial year 2025-26. The record date for this dividend is February 05, 2026, and the payment will be made on or before February 16, 2026.
For the third quarter of FY26, consolidated sales were ₹154,691 million (₹15,469.1 crore), a year-on-year growth of 15.1%. Consolidated net profit stood at ₹33,688 million (₹3,368.8 crore), an increase of 16.0% year-on-year. EBITDA for the quarter was ₹49,485 million (₹4,948.5 crore), up by 23.4%, with an EBITDA margin of 31.9%. Profit before exceptional items and tax was ₹47,166 million (₹4,716.6 crore), up 24.4%.
For the nine-month period ended December 31, 2025, consolidated sales reached ₹436,604 million (₹43,660.4 crore), an increase of 11.3% year-on-year. Net profit for the nine months was ₹87,654 million (₹8,765.4 crore). R&D investment for the nine-month period was ₹25,783 million (₹2,578.3 crore), representing 5.9% of sales.
Global Innovative Medicines sales for Q3FY26 were US$ 423 million, including a US$ 55 million milestone payment. Excluding the milestone, sales grew by 13.2% and accounted for 21.2% of total sales. India Formulation sales for the quarter were ₹49,986 million (₹4,998.6 crore), a growth of 16.2%, contributing 32.3% to total consolidated sales. Sun Pharma maintained its position as India's No. 1 Pharma Company with an increased market share.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.